Pain Intensity Factors Changing Breakthrough Pain Prevalence in Patients with Advanced Cancer: A Secondary Analysis of a Cross-Sectional Observational International Study

Cancer Pain

Factors influencing the use of opioids for breakthrough cancer pain: a secondary analysis of the IOPS-MS study

Eur J Pain.

Mercadante S, Adile C, Masedu F, Marchetti P, Costanzi A, Aielli F

doi: 10.1002/ejp.1339.

Cancer Pain

Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study

J Clin Med.

Mercadante S, Masedu F, Valenti M, Aielli F

doi: 10.3390/jcm9051337.

Cancer PainNeuropathic Pain

Cancer pain with a neuropathic component: a cross-sectional study of its clinical characteristics, associated psychological distress, treatments and predictors at referral to a cancer pain clinic

J Pain Symptom Manage.

Reis-Pina P, Acharya A, Lawlor PG

doi: 10.1016/

RECOMMENDED

Acute PainPostoperative Pain

Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study

Reg Anesth Pain Med.

Habib AS, Kertai MD, Cooter M, Greenup RA, Hwang S

doi: 10.1136/rapm-2018-000040.

COMMENTED

Neuropathic Pain

Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes

★ 3 Recommended and commented by Dr Roland Schreiber, Faculty Member

Pain.

Gylfadottir SS, Christensen DH, Nicolaisen SK, Andersen H, Callaghan BC, Itani M, Khan KS, Kristensen AG, Nielsen JS, Sindrup SH, Andersen NT, Jensen TS, Thomsen RW, Finnerup NB

doi: 10.1097/j.pain.0000000000001744.

Cancer Pain

A randomised, double-blind, crossover, dose ranging study to determine the optimal dose of oral opioid to treat breakthrough pain for patients with advanced cancer already established on regular opioids

Eur J Pain.

Currow DC, Clark K, Louw S, Fazekas B, Greene A, Sanderson CR

doi: 10.1002/ejp.1548.

Cancer Pain

Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study

J Clin Med.

Cuomo A, Cascella M, Forte CA, Bimonte S, Esposito G, De Santis S, Cavanna L, Fusco F, Dauri M, Natoli S, Maltoni M, Morabito A, Mediati RD, Lorusso V, Barni S, Porzio G, Mercadante S, Crispo A

doi: 10.3390/jcm9041003.

Cancer PainNeuropathic Pain

Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study

J Pain Res.

Cascella M, Forte CA, Bimonte S, Esposito G, Romano C, Costanzo R, Morabito A, Cuomo A

doi: 10.2147/JPR.S181079.

Which factors can aid clinicians to identify a risk of pain during the following month in patients with bone metastases? A longitudinal analyses

Support Care Cancer.

Habberstad R, Hjermstad MJ, Brunelli C, Kaasa S, Bennett MI, Pardon K, Klepstad P

doi: 10.1007/s00520-018-4405-9.

Related content

Factors influencing the use of opioids for breakthrough cancer pain: a secondary analysis of the IOPS-MS study

Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study

Cancer pain with a neuropathic component: a cross-sectional study of its clinical characteristics, associated psychological distress, treatments and predictors at referral to a cancer pain clinic

Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study

Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes

A randomised, double-blind, crossover, dose ranging study to determine the optimal dose of oral opioid to treat breakthrough pain for patients with advanced cancer already established on regular opioids

Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study

Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study

Which factors can aid clinicians to identify a risk of pain during the following month in patients with bone metastases? A longitudinal analyses